A Phase 2b, Multinational, Randomized, Double-blind Study to Investigate the Efficacy and Safety of Redasemtide (S-005151) Compared With Placebo in Adult Participants With Acute Ischemic Stroke
A Phase 2b, Multinational, Randomized, Double-blind Study to Investigate the Efficacy and Safety of Redasemtide (S-005151) Compared With Placebo in Adult Participants With Acute Ischemic Stroke
The purpose of this study is to evaluate the efficacy and safety of redasemtide in adult participants with acute ischemic stroke (AIS). This study consists of 2 cohorts, Cohort A and Cohort B. Cohort A (redasemtide or placebo) will enroll participants who are ineligible for systemic thrombolysis and/or mechanical recanalization therapy. Cohort B (redasemtide or placebo) will enroll participants who are eligible to receive or who have received systemic thrombolysis and/or mechanical recanalization therapy as standard of care.
Key Inclusion Criteria:
Key Exclusion Criteria:
Note: Other protocol-defined Inclusion/Exclusion criteria may apply.
Rochester, Minnesota 55905-0001, United States
Miskolc, Borsod-Abauj Zemplen county 3526, Hungary
Fukuoka, Fukuoka 811-0213, Japan
Kitakyushu-Shi, Fukuoka 800-0057, Japan
Omuta-Shi, Fukuoka 836-8567, Japan
Takayama-Shi, Gifu 506-8550, Japan
Higashihiroshima-Shi, Hiroshima 739-0041, Japan
Kure-Shi, Hiroshima 737-0023, Japan
Kurume-Shi, Hukuoka 830-8543, Japan
Nishinomiya-Shi, Hyôgo 663-8501, Japan
Odawara-Shi, Kanagawa 250-0001, Japan
Beppu-Shi, Oita Prefecture 874-0011, Japan
Suita-Shi, Osaka 564-8565, Japan
Suita-Shi, Osaka 565-0871, Japan
Kuki-shi, Saitama 346-8530, Japan
Hamada-Shi, Shimane 697-8511, Japan
Aoi-Ku, Shizuoka 420-8630, Japan
Hamamatsu, Shizuoka 430-8525, Japan
Kakegawa-Shi, Shizuoka 436-8555, Japan
Meguro-Ku, Tokyo 153-0051, Japan
Yonezawa-Shi, Yamagata 992-0033, Japan